Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery
Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
This phase Ib trials studies the side effects and best dose of eribulin mesylate when given
together with radiation therapy in treating patients with retroperitoneal liposarcoma that
can be removed by surgery. Drugs used in chemotherapy, such as eribulin mesylate, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy
x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may
kill more tumor cells.
Phase:
Phase 1
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Eisai Inc. National Cancer Institute (NCI) Oregon Health and Science University